Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | RXRA | P19793 | 2/20 | 0.52 |
| ▸ | OXER1 | Q8TDS5 | 2/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.52 |
| ▸ | PPARD | Q03181 | 5/20 | 0.41 |
| ▸ | PPARA | Q07869 | 5/20 | 0.41 |
| ▸ | TERT | O14746 | 3/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.41 |
| ▸ | F7 | P08709 | 3/20 | 0.41 |
| ▸ | F3 | P13726 | 3/20 | 0.41 |
| ▸ | BLM | P54132 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | FABP4 | P15090 | 3/20 | 0.41 |
| ▸ | TOP1 | P11387 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9738715 | 1.00 | PPARG (0.52) | PPARGMAPTCYP19A1ALDH1A1RXRA | |
| SCHEMBL9201429 | 1.00 | PPARG (0.52) | PPARGMAPTCYP19A1ALDH1A1RXRA | |
| SCHEMBL13931836 | 0.87 | PPARG (0.55) | PPARGMAPTCYP19A1ALDH1A1RXRA | |
| SCHEMBL8458410 | 0.84 | PPARG (0.63) | PPARGMAPTCYP19A1ALDH1A1OXER1 | |
| SCHEMBL27534724 | 0.83 | PPARG (0.48) | PPARGMAPTCYP19A1ALDH1A1RXRA | |
| SCHEMBL1786831 | 0.82 | ALDH1A1 (0.39) | PPARGMAPTCYP19A1ALDH1A1RXRA | |
| SCHEMBL1786833 | 0.82 | ALDH1A1 (0.39) | PPARGMAPTCYP19A1ALDH1A1RXRA | |
| SCHEMBL12320543 | 0.82 | PPARG (0.52) | PPARGMAPTCYP19A1ALDH1A1RXRA | |
| SCHEMBL176453 | 0.80 | PPARG (0.64) | PPARGMAPTCYP19A1ALDH1A1RXRA | |
| SCHEMBL2540034 | 0.80 | PPARG (0.64) | PPARGMAPTCYP19A1ALDH1A1RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240408180-A1 | IONIC LIQUIDS FOR DRUG DELIVERY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-12-12 | — | — | US | disclosed |
| EP-4412587-A1 | IONIC LIQUIDS FOR DRUG DELIVERY | President And Fellows Of Harvard College (US) | 2024-08-14 | — | — | EP | disclosed |
| WO-2023059846-A1 | IONIC LIQUIDS FOR DRUG DELIVERY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-04-13 | — | — | WO | disclosed |
| WO-2022271537-A1 | COMPOSITIONS AND METHODS RELATING TO INJECTABLE MICROEMULSIONS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-12-29 | — | — | WO | disclosed |
| US-20220257767-A1 | IONIC LIQUIDS FOR DRUG DELIVERY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-08-18 | — | — | US | disclosed |
| EP-3946261-A1 | IONIC LIQUIDS FOR DRUG DELIVERY | President And Fellows Of Harvard College (US) | 2022-02-09 | — | — | EP | disclosed |
| CN-113939273-A | Ionic liquids for drug delivery | 哈佛大学校长及研究员协会 | 2022-01-14 | — | — | CN | disclosed |
| WO-2020205409-A1 | IONIC LIQUIDS FOR DRUG DELIVERY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-10-08 | — | — | WO | disclosed |
| EP-0391652-B1 | Interphenylène 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs useful in the treatment of thrombotic and vasopastic disease | SQUIBB & SONS INC (US) | 1995-03-15 | — | — | EP | disclosed |
| US-5153327-A | 7-Oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease | E. R. SQUIBB & SONS, INC. (US) | 1992-10-06 | — | — | US | disclosed |
| US-5100889-A | Thromboxane A2 receptor antagonists, thromboxane synthetase inhibitor | E. R. SQUIBB & SONS, INC. (US) | 1992-03-31 | — | — | US | disclosed |
| EP-0391652-A1 | Interphenylène 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs useful in the treatment of thrombotic and vasopastic disease | E.R. SQUIBB & SONS, INC. (US) | 1990-10-10 | — | — | EP | disclosed |
| EP-0374952-A2 | 7-Oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease | E.R. SQUIBB & SONS, INC. (US) | 1990-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220257767-A1 | IONIC LIQUIDS FOR DRUG DELIVERY | SLCO4C1, SLC47A1, ABCB11 | PPARG 2668/4885MAPT 170/4885CYP19A1 4398/4885 |
| US-20240408180-A1 | IONIC LIQUIDS FOR DRUG DELIVERY | SLCO4C1, SLC47A1, ABCB11 | PPARG 2668/4885MAPT 170/4885CYP19A1 4398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.